Ocugen (OCGN) EBITDA Margin (2014 - 2026)
Ocugen's (OCGN) quarterly EBITDA Margin came in at 1163.67% in Q1 2026, down 18453.0% YoY from N/an in Q1 2025, and down 113.21% on a QoQ basis from 8805.7% in Q4 2025.
Powered by 
Analysis
Ocugen (OCGN) EBITDA Margin (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 7 years of EBITDA Margin data on file, last reported at 1163.67% in Q1 2026.
- Quarterly EBITDA Margin fell 18453.0% year-over-year to 1163.67% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1483.85% (down 22242.0% YoY) and the FY2025 annual result came in at 1425.7%, down 7534.0% from the prior year.
- EBITDA Margin fell to 1163.67% in Q1 2026, from 8805.7% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 8805.7% in Q4 2025 to a low of 5388.41% in Q3 2022.
- A 5-year average of 1539.43% and a median of 1204.73% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 149809 bps — and 2025, when it surged 1061722 bps.
- Tracing OCGN's EBITDA Margin over 5 years: stood at 2657.0% in 2022, then surged by 69 bps to 817.96% in 2023, then plunged by 121 bps to 1811.52% in 2024, then soared by 586 bps to 8805.7% in 2025, then sank by 113 bps to 1163.67% in 2026.
- The last three EBITDA Margin figures came in at 1163.67% (Q1 2026), 8805.7% (Q4 2025), and 1005.99% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | -1,105.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,105.11% |
| Mar 31, 2026 | -1,163.67% |
| Dec 31, 2025 | 8,805.70% |
| Sep 30, 2025 | -1,005.99% |
| Jun 30, 2025 | -1,004.73% |
| Mar 31, 2025 | -979.14% |
| Dec 31, 2024 | -1,811.52% |
| Sep 30, 2024 | -1,166.55% |
| Jun 30, 2024 | -1,353.99% |
| Mar 31, 2024 | -1,204.73% |
| Dec 31, 2023 | -817.96% |
| Sep 30, 2023 | -336.06% |
| Jun 30, 2023 | -4,853.61% |
| Mar 31, 2023 | -4,071.11% |
| Dec 31, 2022 | -2,657.00% |
| Sep 30, 2022 | -5,388.41% |
| Jun 30, 2022 | -3,355.52% |
| Mar 31, 2022 | -3,806.00% |
| Jun 30, 2020 | -7,827.91% |
| Sep 30, 2014 | -1.49% |